Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study

[1]  C. Portwine,et al.  Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline , 2019, Pediatric blood & cancer.

[2]  J. Krischer,et al.  Risk factors for chemotherapy‐induced nausea in pediatric patients receiving highly emetogenic chemotherapy , 2019, Pediatric blood & cancer.

[3]  C. Portwine,et al.  Guideline for the prevention of acute chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A focused update , 2017, Pediatric blood & cancer.

[4]  J. Leeder,et al.  Aprepitant and fosaprepitant drug interactions: a systematic review , 2017, British journal of clinical pharmacology.

[5]  E. Deeks,et al.  Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting , 2017, Drugs.

[6]  L. Wagner,et al.  Treatment pathway of bone sarcoma in children, adolescents, and young adults , 2017, Cancer.

[7]  M. Di Maio,et al.  Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life – An Italian survey , 2017, European journal of cancer care.

[8]  P. Nathan,et al.  Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate , 2016, Supportive Care in Cancer.

[9]  C. Portwine,et al.  Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients , 2013, Pediatric blood & cancer.

[10]  C. Portwine,et al.  Symptom assessment in children receiving cancer therapy: the parents’ perspective , 2010, Supportive Care in Cancer.

[11]  P. Hinds,et al.  Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. , 2009, European journal of cancer.

[12]  A. Taddio,et al.  Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents , 2006, Pharmacotherapy.

[13]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Dupuis,et al.  2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children , 2016, Supportive Care in Cancer.

[15]  Stephen Szabo,et al.  Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. , 2014, Journal of oncology practice.

[16]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Cohen,et al.  Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. , 1995, Pediatric hematology and oncology.